CN1134452C - 新的维生素d受体相关多肽、编码其的核苷酸序列及其用途 - Google Patents

新的维生素d受体相关多肽、编码其的核苷酸序列及其用途 Download PDF

Info

Publication number
CN1134452C
CN1134452C CNB988112264A CN98811226A CN1134452C CN 1134452 C CN1134452 C CN 1134452C CN B988112264 A CNB988112264 A CN B988112264A CN 98811226 A CN98811226 A CN 98811226A CN 1134452 C CN1134452 C CN 1134452C
Authority
CN
China
Prior art keywords
vdrr
polypeptide
leu
glu
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988112264A
Other languages
English (en)
Chinese (zh)
Other versions
CN1279689A (zh
Inventor
J����ķ����
A·伯肯斯塔姆
M·达尔伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9703745A external-priority patent/SE9703745D0/xx
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of CN1279689A publication Critical patent/CN1279689A/zh
Application granted granted Critical
Publication of CN1134452C publication Critical patent/CN1134452C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB988112264A 1997-10-14 1998-08-31 新的维生素d受体相关多肽、编码其的核苷酸序列及其用途 Expired - Fee Related CN1134452C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE9703745A SE9703745D0 (sv) 1997-10-14 1997-10-14 New receptors
SE97037451 1997-10-14
SE9703745-1 1997-10-14
SE98011489 1998-03-31
SE9801148A SE9801148D0 (sv) 1997-10-14 1998-03-31 New receptors
SE9801148-9 1998-03-31

Publications (2)

Publication Number Publication Date
CN1279689A CN1279689A (zh) 2001-01-10
CN1134452C true CN1134452C (zh) 2004-01-14

Family

ID=26663102

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988112264A Expired - Fee Related CN1134452C (zh) 1997-10-14 1998-08-31 新的维生素d受体相关多肽、编码其的核苷酸序列及其用途

Country Status (9)

Country Link
EP (1) EP1023323A1 (enrdf_load_stackoverflow)
JP (1) JP2001519441A (enrdf_load_stackoverflow)
KR (1) KR20010031120A (enrdf_load_stackoverflow)
CN (1) CN1134452C (enrdf_load_stackoverflow)
AU (1) AU732079B2 (enrdf_load_stackoverflow)
CA (1) CA2306453A1 (enrdf_load_stackoverflow)
NZ (1) NZ504025A (enrdf_load_stackoverflow)
SE (1) SE9801148D0 (enrdf_load_stackoverflow)
WO (1) WO1999019354A1 (enrdf_load_stackoverflow)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044216A4 (en) * 1997-12-12 2001-10-31 Merck & Co Inc DNA MOLECULES ENCODING HUMAN NUCLEAR RECEPTOR PROTEINS, nNR7 AND nNR7-1
US6984773B1 (en) 1998-01-09 2006-01-10 The Salk Institute For Biological Studies Transgenic mice expressing a human SXR receptor polypeptide
US6756491B2 (en) * 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
US6911537B2 (en) * 1998-01-09 2005-06-28 The Salk Institute For Biological Studies Xenobiotic compound modulated expression systems and uses therefor
AU2003200641B2 (en) * 1998-01-09 2008-04-03 The Salk Institute For Biological Studies Novel Steroid-activated Nuclear Receptors and Uses therefor
EP1066320A4 (en) * 1998-03-27 2005-03-16 Glaxo Group Ltd ORPHAN NUCLEAR RECEPTOR
US7238491B1 (en) 1998-03-27 2007-07-03 Smithkline Beecham Corporation Pregnane X receptor method
FR2801311B1 (fr) * 1999-11-22 2005-08-26 Centre Nat Rech Scient Polypeptides derives du recepteur nucleaire de la vitamine d, et leurs utilisations notamment dans le cadre du criblage d'analogues de la vitamine d
AU2006200258B2 (en) * 1999-12-09 2009-04-09 The Salk Institute For Biological Studies Novel steroid-activated nuclear receptors and uses therefor
US6514941B1 (en) 1999-12-10 2003-02-04 Campina Melkunie B.V. Method of preparing a casein hydrolysate enriched in anti-hypertensive peptides
US20040053866A1 (en) * 2002-08-21 2004-03-18 The Regents Of The University Of California Tumor suppressor genes and their uses
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504438A (ja) * 1988-03-30 1991-10-03 アーチ　デベロプメント　コーポレイション アンドロジェンレセプターを含むｄｎａ結合蛋白質
ATE215601T1 (de) * 1991-09-17 2002-04-15 Salk Inst For Biological Studi Rezeptoren der steroid/thyroid superfamilie von rezeptoren
US5756448A (en) * 1992-02-26 1998-05-26 The General Hospital Corporation Constitute activator of retinoid (CAR) receptor polypeptides
WO1996022390A1 (en) * 1995-01-17 1996-07-25 The Salk Institute For Biological Studies Methods, polypeptides, nucleotide sequence of xor-6, a vitamin d-like receptor from xenopus
AU5426596A (en) * 1995-05-16 1996-11-29 Salk Institute For Biological Studies, The Modulators for new members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
WO1999019354A9 (en) 1999-12-02
JP2001519441A (ja) 2001-10-23
EP1023323A1 (en) 2000-08-02
CA2306453A1 (en) 1999-04-22
AU732079B2 (en) 2001-04-12
WO1999019354A1 (en) 1999-04-22
SE9801148D0 (sv) 1998-03-31
NZ504025A (en) 2003-04-29
AU9013198A (en) 1999-05-03
KR20010031120A (ko) 2001-04-16
CN1279689A (zh) 2001-01-10

Similar Documents

Publication Publication Date Title
CN1134452C (zh) 新的维生素d受体相关多肽、编码其的核苷酸序列及其用途
AU731087B2 (en) KCNQ potassium channels and methods of modulating same
JP2003024085A (ja) 腫瘍壊死関連受容体ｔｒ７
JPH1169985A (ja) 慢性腎不全の標的およびマーカーであるＣＲＦＧ−１ａ
JPH10504714A (ja) ヒトカリウムチャンネル１および２タンパク質
JPH10337189A (ja) 新規化合物
EP1190089A2 (en) Methods of treatment using lig 72a and variants thereof
CN1280617A (zh) Tsa305基因
CN1313297A (zh) 具有抑制癌细胞生长功能的新的人蛋白及其编码序列
CN1286698A (zh) 人血管紧张素ⅱ/血管升压素受体样基因
JP2003506026A (ja) 哺乳動物サイトカイン；関連試薬
CN1288057A (zh) 一种编码新的人血管紧张素ⅱ－1受体相关蛋白的基因及其应用和制备方法
MXPA00003667A (en) Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
CN1324820A (zh) 具有抑制癌细胞生长功能的新的人蛋白及其编码序列
JPH1132785A (ja) 慢性腎不全の標的およびマーカーであるｃｒｆｇ−１
WO2001046439A1 (fr) Nouveau polypeptide, proteine dnaj humaine 39, et polynucleotide codant pour ce polypeptide
CN1323803A (zh) 具有抑制癌细胞生长功能的新的人蛋白及其编码序列
CN1351081A (zh) 具有抑制癌细胞生长功能的新的人蛋白及其编码序列
CN1470524A (zh) 一种多肽——人转录延伸因子iis51和编码这种多肽的多核苷酸
US20040087525A1 (en) Polypeptide-human rna binding protein 19 and the polynucleotide encoding it
JPH1169984A (ja) 慢性腎不全の標的およびマーカーであるＣＲＦＧ−１ｂ
CN1324819A (zh) 具有抑制癌细胞生长功能的新的人蛋白及其编码序列
CN1303866A (zh) 一种新的多肽——锌指蛋白36和编码这种多肽的多核苷酸
CN1351079A (zh) 具有抑制癌细胞生长功能的新的人蛋白及其编码序列
CN1477120A (zh) 一种多肽—人组织阴离子转运多肽41和编码这种多肽的多核苷酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BIOVITRUM AB

Free format text: FORMER OWNER: PHARMACIA CO.

Effective date: 20020530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20020530

Address after: Stockholm

Applicant after: Biovitrum AB

Address before: Stockholm

Applicant before: Pharmacia Co.

C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee